Osirid (Torasemide Sodium)

Torasemide blocks the sodium‑potassium‑chloride cotransporter in the thick ascending limb of the loop of Henle. This inhibition prevents reabsorption of these ions, leading to increased urinary excretion of water and electrolytes, which reduces extracellular fluid volume and lowers blood pressure.

The exact dose of Osirid is determined by the prescribing clinician based on the individual’s medical condition, severity, renal function, and response to therapy. Dosage adjustments may be required during treatment, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Torasemide is classified as a pregnancy category C medication, meaning it should only be used when the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should discuss alternatives with their healthcare provider.

To request Osirid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any required import documentation.

Osirid (torasemide) offers a longer duration of action and a more predictable electrolyte profile compared with furosemide, another common loop diuretic. It may require once‑daily dosing, whereas furosemide often needs multiple daily doses. Both are effective for edema, but individual response and tolerance guide the choice.

Osirid tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain potency throughout its shelf life.

Osirid is taken orally, usually with a glass of water. It can be administered with or without food, but patients should follow the prescriber’s guidance regarding timing relative to meals to avoid gastrointestinal discomfort.

The most serious risks include severe dehydration, which can lead to hypotension and organ hypoperfusion, acute kidney injury manifested by a rapid rise in serum creatinine, and rare allergic reactions such as rash, swelling, or anaphylaxis. Prompt medical attention is required if these symptoms occur.

Patients with known hypersensitivity to torasemide or other sulfonamide‑derived drugs should avoid Osirid. It is also contraindicated in individuals with anuria, severe electrolyte disturbances, or uncontrolled severe hypertension without appropriate monitoring. Clinicians should assess each patient’s medical history before initiating therapy.